McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxy- genase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633 44. 468. Deleted in press. 469. de Feyter PJ, Serruys PW, Arnold A, et al. Coronary angioplasty of the unstable angina related vessel in patients with multivessel disease. Eur Heart J. 1986;7:460 7. 470. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523 34. 471. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292:2849 59. 472. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA. 2002;288:321 33. 473. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post- menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605 13. 474. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized tri- als of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842 57. 475. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1481 501. 476. Lonn E,Yusuf S,Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567 77. 477. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578 88. 478. Stampfer MJ, Malinow MR, Willett WC, et al. 